Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
Want to see AU:LDX full AI Analyst Report?
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)5.63M
Market Cap
AU$115.48M
Enterprise ValueAU$77.92M
Total Cash (Recent Filing)AU$3.00M
Total Debt (Recent Filing)AU$11.85M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding923,874,150
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.96
Price to Sales (P/S)0.97
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$21.39M
Bulls Say, Bears Say
Bulls Say
6-year Exclusive U.S. PHASE Distribution AgreementA multi-year exclusive distribution contract with a guaranteed minimum creates durable revenue visibility and lowers go-to-market execution risk in the U.S. market. This backlog de-risks early commercial spend, supports scale-up planning, and gives predictable demand to justify capacity and sales investments.
Medicare/MAC Reimbursement Secured (USD 41.38/test)Confirmed reimbursement at a material rate materially improves unit economics for physician-office adoption. Durable payer coverage reduces a major structural barrier to uptake, supports predictable pricing for customers, and makes scaling physician-office use commercially viable over the medium term.
Rising Product Revenue And Strong Gross MarginsRapid product revenue growth plus high gross margins indicate the business model can scale profitably as volumes rise. High product margins (>60%) provide leverage to cover fixed costs, improve operating leverage, and support sustainable cash generation as commercial adoption increases over the next 2-6 months.
Bears Say
Declining Revenue And Persistent LossesRevenue decline and ongoing net/EBIT losses reflect structural challenges converting gross margin into sustainable profitability. Persistent losses reduce internal funding capacity, increase dependence on external capital, and can constrain investments needed for commercial scale without clear, sustained revenue recovery.
High Leverage And Weak Balance Sheet MetricsMaterial leverage and negative returns on equity limit financial flexibility and raise refinancing risk. High debt levels constrain the company's ability to fund manufacturing scale‑up or absorb commercial setbacks, increasing the probability of dilutive or costly financing if cash generation doesn't improve.
Commercial Upside Contingent On CLIA Waiver; Scaling NeedsKey commercial expansion hinges on regulatory CLIA-waiver approval; until granted, addressable market and PHASE-driven volumes remain uncertain. Even with approval, the company must fund manufacturing scale‑up and distribution execution, creating execution and financing risk over the medium term.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.03 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$115.48M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 99 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 923,874,150 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.843%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:LDX Sentiment 91%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$119.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
551.51%
12-Months-Change
Fundamentals
Return on Equity
-164.12%
Trailing 12-Months
Asset Growth
-26.05%
Trailing 12-Months
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---